RESEARCH MONOGRAPH · KDC-MN-277

Letrozole

May 9, 2026 Kodiac biolabs Research Revised May 30, 2026 3 min read

Our opinion on this compound

86/100

Most potent of the non-steroidal AIs and reliably the right choice when complete aromatase suppression is needed

Letrozole is anastrozole's slightly more potent cousin, and the difference matters more than the structural similarity suggests. Novartis's triazole-based AI achieves slightly higher aromatase inhibition (>99% versus >97% for anastrozole) at clinical doses, which translates to lower residual circulating estradiol in postmenopausal women. Whether that 2-3% difference in residual estrogen suppression translates into meaningfully different clinical outcomes is a question that head-to-head trials (notably the FACE trial) have explored, with results that are real but small.

The mechanism is the same non-steroidal AI story. Reversible competitive inhibition of CYP19 aromatase, with high selectivity over other steroidogenic CYP enzymes. The benzhydryltriazole scaffold differs from anastrozole's substituted-benzene structure, and the binding kinetics and tissue distribution profiles are slightly different.

What we like is the indication breadth. Beyond postmenopausal breast cancer where letrozole is established, the compound has interesting roles in ovulation induction (often as a first-line alternative to clomiphene since the Pregnancy in PCOS II trial) and in gynecomastia management in male research contexts. The off-label male endocrine work is some of the more interesting non-oncology pharmacology in the AI class.

The ovulation induction story is particularly interesting because it inverts the original concern that letrozole might be teratogenic. Initial case reports raised that concern; subsequent large trials have largely refuted it, and letrozole-induced ovulation now has reasonable evidence support compared to clomiphene in some PCOS populations. For research-use contexts the female reproductive endocrinology applications are increasingly important.

What we dont like is mostly the same clinical context issues as anastrozole. Bone loss with prolonged complete estrogen suppression is real, the lipid changes are predictable, and arthralgia is a dose-limiting symptom in a meaningful fraction of long-term users.

For research-tool use letrozole is the choice when you want maximum aromatase suppression. The in vitro IC50 is in the low nanomolar range, and the binding kinetics are well-characterized for tool-compound work.

Sourcing is excellent. Off-patent globally, multiple generic manufacturers, pharmacopoeial quality available. Research-grade material is straightforward.

Workhorse with broader applicability than its breast cancer indication suggests. Mechanism is clean, reliability is high, the male endocrine and female reproductive uses extend its research relevance well beyond the original cancer context.

Evidence: 92
Mechanism: 92
Reliability: 90
Safety: 75
Sourcing: 92
Value: 85
Signal: 78
Staying power: 85

Plain-language summary Intrigue 62 / 100

Letrozole (Femara) is the most potent of the three approved aromatase inhibitors, suppressing plasma estradiol by 88 to 99 percent at a 2.5 mg dose (compared to roughly 80 percent for anastrozole). Approved in 1997 for postmenopausal breast cancer, with slight progression-free survival advantages over anastrozole in head-to-head trials. It is also widely used off-label for ovulation induction (often preferred over clomiphene in polycystic ovary syndrome) and by anabolic steroid users for aggressive estrogen control. The greater potency cuts both ways: more reliable estrogen suppression but more pronounced joint stiffness, fatigue, and bone loss. Not stocked by Kodiac. This monograph is provided for research and educational reference.

Intrigue 0–100 blends mechanism novelty, evidence strength, and translational potential. Kodiac editorial, not peer-reviewed.

Non-steroidal aromatase inhibitor (third generation)

A potent non-steroidal aromatase inhibitor; superior to anastrozole at suppressing plasma estradiol and used in postmenopausal breast cancer and ovulation induction.

Abstract

Letrozole (4,4'-(1H-1,2,4-triazol-1-ylmethylene)bis(benzonitrile); CAS 112809-51-5; molecular formula C17H11N5; molecular weight 285.31) is a non-steroidal third-generation aromatase inhibitor developed at Novartis and approved by the FDA in 1997 under the trade name Femara. The compound is a more potent aromatase inhibitor than anastrozole, reducing plasma estradiol by approximately 88 to 99 percent at a 2.5 mg dose in postmenopausal women. The greater potency translates to slightly superior progression-free survival in head-to-head trials versus anastrozole in metastatic breast cancer, with similar tolerability. Plasma half-life is approximately 42 hours; metabolism is hepatic via CYP2A6 and CYP3A4. Approved indications include adjuvant and metastatic ER-positive postmenopausal breast cancer; off-label use in PCOS-related anovulatory infertility (often more effective than clomiphene per the PPCOS II trial) and as estrogen control in androgen-using populations. Used as the most potent reference aromatase inhibitor.

Mechanism of action

Reversible competitive aromatase (CYP19) inhibition with greater potency than anastrozole. Plasma estradiol suppression 88 to 99 percent.

Reported research dose ranges

Clinical 2.5 mg in the published literature. Ovulation induction 2.5 to 7.5 mg for 5 days. Off-label estrogen control 0.25 to 0.5 mg every other day.

References

Bhatnagar AS. The discovery and mechanism of action of letrozole. Breast Cancer Res Treat 2007.
Mouridsen H, et al. Phase III study of letrozole versus tamoxifen as first-line therapy of advanced breast cancer in postmenopausal women. J Clin Oncol 2003.
Legro RS, et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome (PPCOS II). N Engl J Med 2014.

Read the full monograph

The full reference document is available as a research-use-only PDF download. Note: PDFs for newly added compounds may take a few hours to propagate after this article was published.

KDC-MN-277

The full reference document is provided strictly for research use only. It reports research dose ranges from the published literature, not instructions for use in humans or animals.

Download PDF →

FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human consumption. All information is provided for research and educational purposes only.

Kodiac sells research compounds for investigative use only.

Letrozole

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Quick actions

Categories

Help and policies

Abstract

Mechanism of action

Reported research dose ranges

References

Read the full monograph

Adjacent monographs